Trastuzumab (Herceptin®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000338
English
Authors' recommendations:
Trastuzumab (Herceptin®) is recommended as an option for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. This submission covers the licence extensions for treatment with trastuzumab:
following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel;
in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin.
AWMSG is of the opinion that trastuzumab (Herceptin®) is suitable for specialist only prescribing within NHS Wales for the above indication.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=191139&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Antibodies, Monoclonal, Humanized
- Breast Neoplasms
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.